期刊文献+

缬沙坦对尿酸性肾病大鼠肾间质纤维化的干预机制研究 被引量:6

Intervention Mechanism of Valsartan on Renal Interstitial Fibrosis in Uric Acid Nephropathy Rats
下载PDF
导出
摘要 目的观察尿酸性肾病大鼠肾脏血小板反应蛋白-1(TSP-1)和缺氧诱导因子-1α(HIF-1α)的表达及缬沙坦对其影响,探讨缬沙坦对尿酸性肾病大鼠肾间质纤维化的干预机制。方法选取雄性健康Wistar大鼠36只为研究对象,适应性喂养1周后,采用随机数字表法分为正常组、模型组和缬沙坦组,每组12只。采用酵母和腺嘌呤建立尿酸性肾病模型,造模同时给予缬沙坦干预。于入组3周和5周时观察3组大鼠血尿酸(UA)、血肌酐(Scr)及肾脏病理变化,采用免疫组织化学法和逆转录聚合酶链反应(RT-PCR)法检测肾脏TSP-1和HIF-1α的表达。结果 3组大鼠3周和5周时测得的体质量、UA、Scr水平比较,差异均有统计学意义(P<0.05)。模型组和缬沙坦组大鼠3周、5周时的体质量低于正常组大鼠,UA、Scr水平高于正常组大鼠,差异均有统计学意义(P<0.05);模型组大鼠3周和5周时的体质量低于缬沙坦组,Scr水平高于缬沙坦组,差异均有统计学意义(P<0.01)。3组大鼠3周和5周时RT-PCR测得的TSP-1 mRNA、HIF-1αmRNA表达量比较,差异均有统计学意义(P<0.05)。模型组和缬沙坦组3周和5周时TSP-1 mRNA、HIF-1αmRNA的表达量均高于正常组(P<0.01),模型组3周和5周时TSP-1 mRNA、HIF-1αmRNA的表达量亦均高于缬沙坦组,差异有统计学意义(P<0.05)。模型组大鼠3周和5周时肾组织TSP-1 mRNA与HIF-1αmRNA的表达分别呈正相关(r值分别为0.821和0.736,P<0.05)。结论尿酸性肾病的发展存在缺氧状态;缬沙坦可能通过下调TSP-1及HIF-1α的表达改善肾脏纤维化程度。 Objective To investigate the expression of thrombospondin - 1 ( TSP - 1 ) and hypoxia - inducible factor - 1α ( HIF -1α) in uric acid nephropathy rats and the effect of Valsartan in order to understand the intervention mechanism of Valsartan on renal interstitial fibrosis. Methods 36 male Wistar rats were selected and were randomly divided into normal group, model group and valsartan group with each group 12 rats. Yeast and adenine were used to establish uric acid nephropathy, and meanwhile, valsartan intervention was also performed. After three and five weeks, UA, Scr and renal histological changes were observed. Immunohistochemieal method and RT - PCR method was used to detect the expression of TSP - 1 and HIF - 1α. Results The body weight, UA and Set between the three groups at three and five weeks all showed statistically significant differ- ences ( P 〈 0. 05 ) . The body weight of model group and valsartan group at three and five weeks was significantly lower than the normal group, while the UA and Ser were significantly higher than the normal group ( P 〈 0. 05 ) . The body weight of the model group at three and five weeks was significantly lower than the valsartan group, while the Scr was significantly higher than the val- sartan group ( P 〈 0. 01 ) . The expression of TSP - 1 mRNA and HIF - 1 α mRNA detected by RT - PCR at three and five weeks between the three groups showed statistically significant differences ( P 〈 0. 05 ) . The expression of TSP - 1 mRNA and HIF - 1 α mRNA in model group and valsartan group at three and five weeks were significantly higher than the normal group ( P 〈 0. 01 ) , and the expression of TSP - 1 mRNA and HIF - 1α mRNA in model group was significantly higher than the valsartan group ( P 〈 0.05) . The expression of TSP- 1 mRNA and HIF-1α mRNA in model group at three and five weeks was positively correlated ( r = 0. 821 and 0. 736, P 〈 0. 05 ) . Conclusion The hypoxia condition exists in uric acid nephropathy rats. Valsartan can im- prove renal interstitial fibrosis by decreasing the expression of TSP - 1 and HIF - 1α.
出处 《中国全科医学》 CAS CSCD 北大核心 2013年第6期644-648,共5页 Chinese General Practice
关键词 尿酸性肾病 肾间质纤维化 缺氧诱导因子-1Α 血小板反应蛋白-1 缬沙坦 Uric acid nephropathy Renal interstitial fibrosis Hypoxia - inducible factor - 1α Thrombospondin - 1 Valsartan
  • 相关文献

参考文献11

  • 1Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final com- mon pathway to end - stage renal failure [ J ]. J Am Soc Nephrol, 2006, 17 (1): 17-25.
  • 2Stravodimos KG, Koritsiadis G, Lazaris AC, et al. Hydronephrosis pro- motes expression of hypoxia - inducible factor - 1 alpha : Jl. Urol Int, 2009, 82 (1): 38-42.
  • 3Ohashi R, Shimizu A, Masuda Y, et al. Peritubular capillary regres- sion during the progression of experimental obstructive nephropathy [Jl. J Am Soc Nephrol, 2002, 13 (7) : 1795 -1805.
  • 4Motegi K, Harada K, Pazouki S, et al. Evidence of a bi - phasia effect of thrombospondin- 1 on angiogenesis [ J]. Histochem J, 2002, 34 (8/9) : 411 -421.
  • 5Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis I J ]. Kidney Int, 1998, 65 (Suppl) : s74 - s78.
  • 6Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinu- ria ? Towards the unifying theme of chronic hypoxia [ J ]. Kidney lnt, 2000, 75 (Suppl): s22-s26.
  • 7Sanchez AP, Sharma K. TranScription factors in the pathogenesis of dia- betic nephropathy [J]. Expert Rev Mol Med, 2009, 28 (ll) : elS.
  • 8Kang DH, Nakagawa T, Feng L, et at. A role for uric acid in the pro- gression of renal disease [J]. J Am Soc Nephrol, 2002, 13 (12) : 2888 - 2897.
  • 9王爱坤.缬沙坦对糖尿病肾病的保护作用研究[J].实用心脑肺血管病杂志,2011,19(9):1513-1513. 被引量:8
  • 10王晓东,李红涛,包春艳,马波,兰丽娟,吴书元,杨涛.瑞舒伐他汀钙联合缬沙坦治疗早期糖尿病肾病疗效观察[J].中国全科医学,2011,14(33):3787-3789. 被引量:21

二级参考文献16

  • 1Bums KD.Angiotensin Ⅱ and its receptors in the diabetic kidney[J].Am J Kidney Dis,2000,36(3):449-467.
  • 2Valk EJ, Bruijn JA, Bajema IM. Diabetic nephropathy in humans: pathologic diversity [ J ]. Curr Opin Nephrol Hypertens, 2011, 20 (3) : 285 - 289.
  • 3Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy [J]. Am j Kidney Dis, 2003, 41 (3 Suppl 1) : S19 -21.
  • 4Kanwar YS, Sun L, Xie P, et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy EJ]. Annu Rev Pathol, 2011, 28 (6) : 395 -423.
  • 5Rosario RF, Prabhakar S. Lipids and diabetic nephropathy [ J ]. Curr Diab Rep, 2006, 6 (6): 455-462.
  • 6Agarwal R. Effects of statins on renal function [ J ]. Am J Cardiol, 2006, 97 (5): 748-755.
  • 7Kalaitzidis R, Bakris GL Effects of angiotensin II ceptor blockers on diabetic nephropathy [J]. J Hypertens Suppl, 2009, 27 (5): 15 - 21.
  • 8Abel T, Feh6r J, Role of rosuvastatin in current lipid - lowering therapy [J]. Orv Hetil, 2010, 151 (35): 1424-1428.
  • 9Laeourcire Y, Poirier L Valsartan is more effective than placebo in re- dueing the incidence of diabetes in people with impaired glucose toler- ance and cardiovascular disease or risk factors but has no effect on cardio- vascular outcomes [ J]. Evid Based Med, 2011, 16 (4) : 122 - 123.
  • 10Abe H. Recent progress in understanding the molecular pathogenesis of diabetic nephropathy [J]. Rinsho Byori, 2011, 59 (2): 179-186.

共引文献27

同被引文献82

  • 1李景花,刘建涛,张自强,孙永康,郑树然.附子理中丸和真武汤加减联合治疗糖尿病肾病脾肾阳虚证的临床研究[J].辽宁中医杂志,2020(5):135-137. 被引量:24
  • 2苏筠霞,刘明龙,刘天喜,肖祖容,李建华.痛风定对尿酸性肾病大鼠肾脏肿瘤坏死因子-α、单核细胞趋化蛋白-1和细胞间黏附分子-1mRNA的影响[J].兰州大学学报(医学版),2013,39(1):6-10. 被引量:7
  • 3高学昌,赵海东.杜仲炮制初探[J].时珍国药研究,1994,5(3):25-26. 被引量:8
  • 4陈欣,王琳,杨汉东,闵新文.缬沙坦对炎性动脉粥样硬化的影响[J].实用医学杂志,2006,22(13):1491-1493. 被引量:6
  • 5Takahashi M. Inflammatory cytokines in the pathogenesis of athemsclerosis [J]. Nippon Rinsho, 2011,69 (1) : 30-36.
  • 6Handayani D, Meyer B J, Chen J,et al. A high-dose Shiitake mushroom increases hepatic accumulation of triacylglyc- erol in rats fed a high-fat diet:underlying mechanism [J]. Nutrients, 2014,6 (2) : 650-662.
  • 7Novgorodtseva TP, Karaman IuK,Zhukova NV. Modification of fatty acid composition of polar and neutral lipids of blood and liver in rat in conditions of prolonged high-fat diet [J]. Biomed Khim,2013,59(6):644-654.
  • 8Han SN,Leka LS,Liehlenstein AH,et al. Effect of hydrogenat- ed and satuated,relative to polyunsaturated,fat on immune and inflammatory responses of adults with moderate hyper- cholesterolermia [J]. J Lipid Res, 2002,43 (3) :445-452.
  • 9Li JJ,Fang CH. Atheroscleritis is a more rational termfor the pathological entity currently known as atheroselerosis [J]. Med Hypotheses, 2004,63 ( 1 ) : 100-102.
  • 10Ridker PM. Rosuvastatin in the primary prevention of car- diovascular disease among patients with low levels of low- density lipoprotein cholesterol and elevated high-sensitiv- ity C-reactive protein rationale and design of the JUPITER trail [J]. Circulation, 2003,108 (19) : 2292-2297.

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部